Life extension effect and patient reference after taking ceritinib/ceritinib (Zanda)

Ceritinib/Ceritinib (Ceritinib) is an oral targeted drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It blocks the proliferation and survival signals of tumor cells by selectively inhibiting ALK tyrosine kinase activity, thereby delaying tumor progression. For ALK positive patients, ceritinib can significantly improve the disease control rate and provide patients with the possibility of extending survival.

Clinical studies have shown that ceritinib can still achieve a high objective response rate (ORR) and median progression-free survival (PFS) in patients who have previously been resistant to crizotinib or other generation ALK inhibitors. For example, in the ASCEND series of studies, the median PFS was about 8 to 16 months, and for ALK inhibitor-naïve patients, the survival prolongation effect was more obvious. Patients can achieve disease stabilization or even partial remission by taking medications regularly, thereby improving their quality of life.

While patients are taking ceritinib, the efficacy should be evaluated based on imaging examinations and clinical symptoms. Although drugs can prolong survival, individual differences are large, and efficacy is affected by factors such as tumor burden, previous treatment history, and drug resistance mechanisms. Doctors usually adjust the dose or combine it with other treatment options based on the patient's specific conditions to maximize the patient's life span and improve their quality of life.

In addition, patients need to pay attention to drug tolerance and side effect management when using ceritinib. Common adverse reactions include diarrhea, abnormal liver function, nausea and loss of appetite. These symptoms are more common in the early stages, but can be effectively controlled through dose adjustment, dietary adjustment and regular monitoring. Overall, ceritinib provides a significant survival benefit for ALK-positive NSCLC patients, but individualized management under the guidance of professional doctors is still needed to achieve optimal efficacy and long-term safety.

Reference materials:https://www.drugs.com/